EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme ( PBS ) Data

Patricia A Logan iD, Peter S Micalos iD, Shanna Fealy iD, Marguerite Bramble iD, Alfred Wong iD

Australian Journal of Rural Health · 2025

DOI: 10.1111/ajr.70094 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Australian Journal of Rural Health, 2025. Verfasst von Patricia A Logan und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Dentistry and Medical Science, Faculty of Science and Health, Charles Sturt University, Bathurst, New South Wales, Australia. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Charles Sturt University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Explore Parkinson's Disease (PD) related prescription patterns for people with PD living in metropolitan and non‐metropolitan areas of New South Wales, Australia.

Methods

Exploratory, cross‐sectional data linkage study. Participants were grouped according to geographic location and by age group: metropolitan or non‐metropolitan; rural, regional, and remote. Prescription patterns were analysed using descriptive and inferential statistics.

Design

The Sax Institute's 45 and Up Study data was linked to the Pharmaceutical Benefits Scheme (PBS) records (2004–2017) for all participants with PD.

Setting

Retrospective data exploration and analysis.

Participants

1648 participants who self‐identified as having PD and voluntarily contributed to the 45 and Up longitudinal study. Main Outcome Measures Statistical comparisons based on location were undertaken for the different groupings for PD‐specific medications.

Results

Significant differences in the proportions of PD‐related medications are observed between locations. Significant differences in the proportions of PD‐related medications are observed between locations. A higher proportion of levodopa and levodopa combinations is reported for major cities (75.5%) compared with the inner region (70.3%) and outer and remote regions (74.1%). Additionally, other PD‐related medications in the non‐metropolitan areas are proportionally higher than those reported for major cities. Analysis by age groups suggests large effect sizes for the 75–79 and 45–49 age groups, while medium and small effect sizes are reported for the 55–59 and 70–74 age groups, respectively.

Conclusion

Inequities with best practice medication treatment for PD exist between metropolitan and non‐metropolitan areas of NSW. Efforts are required to successfully bridge gaps. Upskilling GPs may provide one way to optimise therapy and quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseAntiparkinson AgentsHumansNew South WalesMaleFemaleAgedMiddle AgedCross-Sectional StudiesRetrospective StudiesRural PopulationAged, 80 and overAdultLevodopa

Stichwörter der Autor:innen

medicationsmovement disordersnon‐metropolitanprescriptionsregionalremoterural

Substanzen

Antiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • School of Dentistry and Medical Science, Faculty of Science and Health, Charles Sturt University, Bathurst, New South Wales, Australia.
  • School of Dentistry and Medical Science, Faculty of Science and Health, Charles Sturt Univesity, Port Macquarie, New South Wales, Australia.
  • Faculty of Science and Health, Ageing Well in Rural and Regional Australia Research Group, Charles Sturt University, Bathurst, New South Wales, Australia.
  • School of Nursing, Paramedicine and Healthcare Science, Faculty of Science and Health, Charles Sturt University, Bathurst, New South Wales, Australia.
  • School of Business, Faculty of Business, Justice and Behavioural Science, Charles Sturt University, Bathurst, New South Wales, Australia.

ORCID-Profile: Patricia A Logan, Peter S Micalos, Shanna Fealy, Marguerite Bramble, Alfred Wong

Förderung

  • Charles Sturt University

Zitieren

APA

Logan, P. A., Micalos, P. S., Fealy, S., Bramble, M., & Wong, A. (2025). Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme ( PBS ) Data. Australian Journal of Rural Health. https://doi.org/10.1111/ajr.70094

Vancouver

Logan PA, Micalos PS, Fealy S, Bramble M, Wong A. Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme ( PBS ) Data. Australian Journal of Rural Health. 2025. doi:10.1111/ajr.70094

BibTeX
@article{Logan2025,
  author = {Logan, Patricia A and Micalos, Peter S and Fealy, Shanna and Bramble, Marguerite and Wong, Alfred},
  title = {Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme ( PBS ) Data},
  journal = {Australian Journal of Rural Health},
  year = {2025},
  doi = {10.1111/ajr.70094}
}
Kostenlos starten →